P-0240LIVER RESECTION RATE FOLLOWING DOWNSIZING CHEMOTHERAPY WITH CETUXIMAB IN METASTATIC COLORECTAL CANCER: UK REAL WORLD STUDY

11 pH Associates Limited, Marlow, UK Background: Patient survival in metastatic colorectal cancer (mCRC) can be improved if patients with metastases confined to the liver are able to undergo liver resection. Resectability of liver metastases was improved in clinical trials of downsizing with chemotherapy plus cetuximab. This study describes the liver resection rate achieved in normal UK clinical practice using chemotherapy plus cetuximab in patients whose tumours were originally deemed inoperable by a Hepatobiliary Multi-disciplinary Team (HPBMDT). Methods: A multi-centre retrospective observational study was conducted in 7 UK hospitals with specialised liver surgical services. Included patients had mCRC with metastases confined to the liver, defined locally as unresectable at first review by the